BFH772 (VEGFR2 inhibitor): Technical Protocols and Use Guide

What This Product Solves

BFH772 is a potent, selective small-molecule inhibitor of VEGFR2 kinase, developed to support research on VEGFR2-mediated angiogenesis, with particular applicability in tumor angiogenesis models. Its high affinity (IC50 = 3 nM) and selectivity make it suitable for experiments demanding precise modulation of VEGFR2 signaling, without significant off-target effects on related kinases such as FLK-1, FLT-1, FLT-4, B-RAF, RET, or TIE-2 (product_spec). Researchers seeking to investigate anti-angiogenic mechanisms or to test the roles of VEGFR2 in disease progression can leverage BFH772 for robust, reproducible data. However, its lack of water solubility restricts its use in workflows that require aqueous delivery systems.

For technical guidance, existing resources such as the BFH772 (VEGFR2 inhibitor): Technical Use and Protocol Parameters article provide further discussion on solubility and selectivity constraints, while the Technical Guide for Angiogenesis Research outlines protocol adaptations for tumor model systems.

Protocol Parameters

• assay: In vitro kinase inhibition
  value_with_unit: IC50 = 3 nM
  applicability: Quantitative assessment of VEGFR2 signaling pathway inhibition
  rationale: Enables precise titration and comparison across inhibitors; confirms on-target potency
  source_type: product_spec
• assay: Compound solubility in DMSO
  value_with_unit: ≥53.4 mg/mL
  applicability: Preparation of concentrated stock solutions for cell-based assays
  rationale: Ensures reliable delivery in DMSO-compatible in vitro and in vivo workflows
  source_type: product_spec
• assay: Storage temperature (solid form)
  value_with_unit: -20°C
  applicability: Long-term maintenance of compound integrity
  rationale: Prevents degradation and maintains batch-to-batch consistency
  source_type: product_spec
• assay: Suitability for aqueous workflows
  value_with_unit: Not recommended (insoluble in water)
  applicability: Avoid use in water-based delivery or high-throughput screening requiring water solubility
  rationale: Poor water solubility precludes compatible formulation and may confound results
  source_type: workflow_recommendation

Workflow Setup and QC Checklist

For reliable results, adhere to the following procedural steps and quality control checks:

• Stock Preparation: Dissolve BFH772 in DMSO or ethanol at concentrations up to 53.4 mg/mL or 15.33 mg/mL, respectively. Filter sterilize if required for cell culture.
• Aliquoting and Storage: Prepare small aliquots to minimize freeze-thaw cycles. Store solids and solutions at -20°C. Avoid long-term storage of prepared solutions to prevent degradation (product_spec).
• Purity Verification: Confirm lot purity (≥96%) using the supplied certificate of analysis. Cross-reference batch numbers with the certificate and safety data sheet.
• Vehicle Controls: Always run DMSO or ethanol-only controls at matching concentrations to account for solvent effects in biological assays.
• Experimental Controls: Include positive and negative controls for VEGFR2 inhibition to validate assay responsiveness.
• Documentation: Capture all batch, preparation, and storage details in experimental records to ensure reproducibility and traceability.

Common Failure Modes and Fixes

• Poor Solubility in Aqueous Systems: Symptom: Precipitation or visible turbidity when adding BFH772 to aqueous media.
  Fix: Dilute compound stocks into DMSO or ethanol before further dilution in cell culture media, ensuring that the final organic solvent concentration remains within cell-tolerant limits. Do not use for applications requiring direct water solubility.
• Loss of Activity on Storage: Symptom: Reduced inhibition observed over time.
  Fix: Prepare fresh working solutions for each experiment. Avoid repeated freeze-thaw cycles and prolonged storage of diluted stocks.
• Off-target Effects: Symptom: Unexpected cellular responses not consistent with VEGFR2 inhibition.
  Fix: Review selectivity data (500-fold lower activity for FLK-1, FLT-1, FLT-4, and 40-fold lower for B-RAF, RET, TIE-2). Validate findings with orthogonal assays or alternative inhibitors when possible (product_spec).
• Solvent Toxicity: Symptom: Cell viability loss across all conditions.
  Fix: Ensure that DMSO or ethanol concentrations remain below cytotoxic thresholds for your cell type. Adjust vehicle control conditions accordingly.

Scope and Limitations

BFH772 is best suited for research focusing on selective VEGFR2 signaling pathway inhibition, particularly in tumor angiogenesis models or studies requiring an anti-angiogenic agent with a defined selectivity margin. Its application is limited where broad kinase inhibition or water-soluble compound delivery is necessary. The compound is not intended for use in workflows or assays where water solubility is essential, nor is it appropriate for studies targeting a broad spectrum of receptor tyrosine kinases (internal_article). Additionally, long-term storage of stock solutions is discouraged due to potential degradation.

Conclusion

BFH772 provides a robust tool for researchers investigating VEGFR2-driven angiogenesis, offering high selectivity and potency for targeted studies. For optimal results, leverage its DMSO/ethanol solubility, adhere to storage and handling recommendations, and avoid workflows requiring water solubility or broad kinase inhibition. Additional technical details and protocol adaptations are available from APExBIO (BFH772 (VEGFR2 inhibitor)), as well as in related internal technical guides. Strict adherence to referenced protocol parameters and workflow best practices is essential for data integrity and reproducibility.